Developer of tools for diagnosing immune-mediated inflammatory diseases. The company is developing a pioneering suite of prognostic tools to guide treatment choice and improve patient outcomes in immune-mediated diseases. The company's first product, PredictSURE IBD stratifies patients with IBD (both Crohn’s disease and ulcerative colitis). The company was founded in 2017 and headquartered in Cambridge, United Kingdom. It has raised $18.3M in series b funding, with backing from Parkwalk, University of Cambridge, Wren Capital, Wellcome Trust, and others. The company operates in the HealthTech - Healthcare IT, Life Sciences - Genomics, Life Sciences - Life Sciences Platforms and Tools space. Its offerings span Immunology - In Vitro Diagnostic Tests - Diversified and Genomics - Enabling Te.
PredictImmune
Series BDeveloper of tools for diagnosing immune-mediated inflammatory diseases. The company is developing a pioneering suite of prognostic tools to guide treatment choice and improve patient outcomes in immune-mediated diseases. The company's first product, PredictSURE IBD stratifies patients with IBD (both Crohn’s disease and ulcerative colitis). The company was founded in 2017 and headquartered in Cambridge, United…
About
Business model
Healthcare IT > Provider > Clinical Operations > Decision Support > Diagnosis > Differential Diagnosis > Diagnosis Suite,
Immunology > In Vitro Diagnostic Tests > Diversified,
Genomics > Enabling Technologies > Kits and Reagents > Bioreagents,
Life Sciences Platforms and Tools > Research Reagents and Kits > Genomics > PCR
Institutional investors
Latest coverage
📰 Latest funding news — recent raises and deal signals across the ecosystem.
Backed by funds in our directory
🗂️ Explore HealthTech investors — funds that write checks in this sector.